China Pharma Holdings (CPHI) Net Cash Flow (2010 - 2026)

China Pharma Holdings (CPHI) has reported Net Cash Flow for 17 consecutive years, with $87290.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 65.36% year-over-year to $87290.0; the trailing twelve-month figure through Jun 2026 stood at -$373495.0 (down 2212.66% YoY), and the FY2025 full-year result was -$283017.0, up 61.31% from the prior year.
• Net Cash Flow improved to $87290.0 in Q2 2026 per CPHI's latest filing, from -$134617.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $463427.0 in Q3 2023 and bottomed at -$1.4 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$236299.7 across 5 years, with a median of -$63037.5 in 2022.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow jumped 9298.63% in 2023, then slumped 1194.31% in 2025.
• Over 5 years, Net Cash Flow stood at -$60201.0 in 2022, then jumped by 105.86% to $3528.0 in 2023, then plunged by 905.33% to -$28412.0 in 2024, then jumped by 359.15% to $73631.0 in 2025, then grew by 18.55% to $87290.0 in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $87290.0, -$134617.0, and $73631.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.